Lifemd, Inc. · NASDAQ:LFMD
Lifemd — Immudyne — Investor Presentation (June 2018)
18 slides from Lifemd's investor presentation, Jun 19, 2018
Slide 1: Immudyne, Inc. Q2 2018 Corporate Presentation
IMMUDYNE, INC. Q2 2018 CORPORATE PRESENTATION PLEASE NOTE: OUR NAME WILL BE CHANGING TO CONVERSION LABS, INC. AS OF 7/1/2018 Immudyne, Inc. Q2 2018 Corporate presentation Ticker: IMMD
Slide 2: Safe harbor
Statements in this presentation that are not descriptions of historical facts are forward - looking statements relating to future events, and as such all forward - looking statements are made pursuant to the Securities Litigation Reform Act of 1995 . Statements may contain certain forward - looking
Slide 3: Corporate highlights
immudyne 3 Transformational sales and earnings growth anticipated in 2018 growing Cash flow positive with healthy and growing balance sheet profitable Capital efficient, global marketing technology platform scalable Robust portfolio of IP trade secrets, and trademarks proprietary Immudyne is A techn
Slide 4: Our business model
Our business model PRODUCT development • Build, Create • In - License • Acquire Marketing Technology PLATFORM • CRM System • Email Platform • Media Buying • Retargeting • Analytics • Creative • Development • Processing • Call Center • Fulfillment • Legal/Compliance BRANDING • Products • Websites • A
Slide 5: Shapiro MD: from zero to $2M in quarterly revenue
immudyne 5 Shapiro MD: from zero to $2M in quarterly revenue within first 12 months proven scalability 0 500000 1000000 1500000 2000000 2500000 Prior to Licensing Q3 2017 Q4 2017 Q1 2018 Q2 2018 (Forecast)
Slide 6: Strong corporate revenue growth
Strong corporate revenue growth Leverage our expertise and infrastructure to prove out direct - response ROI Identify & build innovative brands in large markets 5 immudyne 6 0 2000000 4000000 6000000 8000000 10000000 12000000 2013 2014 2015 2016 2017 2018 *Based on run - rate as of 5/22/2018, we bel
Slide 7: 2018 Objectives & catalysts
immudyne 7 we have a big year ahead of us… 2018 Objectives & catalysts • Continue to grow revenue in U.S. • Launch in U.S. retail locations • Launch infomercials in U.S. • China joint venture • Latin America expansion • U.S. Launch Q2 2018 • Expected to contribute to revenue in Q3 2018 • U.S. Launch
Slide 8: Product portfolio
Product portfolio 5 immudyne 8 Our product portfolio is comprised of proprietary online brands that are highly scalable and address large unmet market needs Commercial Commercial Q3 2018* Q3 2018* *Projected launch date which could be delayed due to unforeseen factors. Commercial
Slide 9: Our brands
© Our brands
Slide 10: Shapiro MD: DHT blocking hair care aid
immudyne 10 DHT blocking hair care aid Shapiro MD PHOTO CAPTION Developed by distinguished dermatologists Dr. Steven Shapiro, M.D., and Dr. Michael Borenstein, M.D. PhD 2 U.S. Patents; 15 years of product development and formulation work Contains 3 naturally occurring DHT blocking ingredients 35,000
Slide 11: iNR Wellness: beta glucan immune support supplement
immudyne 11 Beta glucan immune support supplement iNR wellness PHOTO CAPTION Triple - action beta glucan supplement containing high quality yeast, oat and mushroom glucans Contains Immudyne’s proprietary Y,1 - 3 - 1,6 Yeast Beta Glucan Attractive category; immune support is large market with minimal
Slide 12: Scarology
Scarology Scarology is a scar healing solution delivered through a simple, three step day and night routine Three essential ingredients work together to achieve dramatic results in appearance and feel Clinically proven and developed by scar therapy experts and prominent Palm Beach based physicians D
Slide 13: Purpurex: clinically proven nutraceutical for bruising
immudyne 13 Clinically proven nutraceutical for bruising purpurex First and only treatment for solar purpura, a common skin condition which affects ~12% of individuals over the age of 50 worldwide Unique nutraceutical formulation that has been clinically shown to reduce the appearance and duration o
Slide 14: PDF Simpli
immudyne 14 Easily convert pdf or online files PDF Simpli IMMD acquired a 51% stake in PDF Simpli in June 2018 PDF Simpli is a software product to easily convert and edit various types of online documents The top 10 competitors in the space have over 59.34 million unique visits per month on average
Slide 15: Management team
Justin schreiber stefan galluppi Robert kalkstein Juan Piniero Founder of JLS Ventures, a small cap venture capital firm with strong track record Co - founder of Immudyne’s direct marketing business Deep experience in healthcare, technology, and online marketing Largest private investor in IMMD Form
Slide 16: 2018 catalysts and company snapshot
Immudy n e is a technology driven online marketing company creating shareholder value through responsible, long - term growth of our core online brands. fin a ncials 2018 Catalysts: • Revenue growth • Additional licensing deals • Strengthening of executive team • Product endorsements • Uplisting to
Slide 17: Investment summary
Profitable & Growing. I m mudyne is profitable and anticipates significant sales growth in FY201 8 . investment SUMMARY Incredi b le Products. Our portfolio of p r oducts address large unmet needs and are backed by real science and accomplished medical opinion leaders. Large Addressable Market. All
Slide 18: Contact us
immudyne 18 CONTACT US Justin Schreiber President & CEO justin@jlsventures.com 717.381.7492 Robert kalkstein CFO Robert@Immudyne.com 866.351.5907